Exchange: NYSE·Updated 07:59 PM EST

EW News

News
all
press releases
BSX's Weak Solvency and Cash Conversion Raise Financing Risk
Boston Scientific faces rising financing risks as high debt, margin pressures, weaker cash flow expectations and acquisition commitments threaten its financial flexibility.
Zacks
BSX's Weak Solvency and Cash Conversion Raise Financing Risk
Boston Scientific faces rising financing risks as high debt, margin pressures, weaker cash flow expectations and acquisition commitments threaten its financial flexibility.
Zacks
More News
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 9.5% on an annualized basis producing an average annual return of 18.23%. Currently, Edwards Lifesciences has a market capitalizationread more...
Benzinga
Boston Scientific's weak WATCHMAN demand, EP market share losses and lowered 2026 outlook raise concerns over its growth prospects. Is it time to exit?
Zacks
Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $113.00 to $121.00 and gave the company an "overweight" rating in a research note on Monday...
MarketBeat
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty-six ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and twenty-three have issue...
MarketBeat
Aberdeen Group plc increased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 49.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 745,667 shares of the medical...
MarketBeat
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), ExxonMobil Holdings Corporation (XOM) and Pfizer Inc. (PFE).
Zacks
BSX bets on WATCHMAN growth through clinical trials and physician outreach, even as slowing demand and rising competition cloud its outlook.
Zacks
Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open EnrollmentPR NewswireNEW YORK, Nov. 9, 2026 NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Market Updates News Commentary- Health care stocks...
PR Newswire
Hims & Hers Health gears up for Q3 earnings, with weight loss demand, international expansion and subscriber growth fueling revenues despite margin pressures.
Zacks

Advertisement|Remove ads.